GB2553252B - Aptamers that block the catalytic cleft of complement Factor D - Google Patents
Aptamers that block the catalytic cleft of complement Factor D Download PDFInfo
- Publication number
- GB2553252B GB2553252B GB1718801.2A GB201718801A GB2553252B GB 2553252 B GB2553252 B GB 2553252B GB 201718801 A GB201718801 A GB 201718801A GB 2553252 B GB2553252 B GB 2553252B
- Authority
- GB
- United Kingdom
- Prior art keywords
- aptamer
- cases
- aptamers
- factor
- less
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108091023037 Aptamer Proteins 0.000 title claims description 400
- 230000003197 catalytic effect Effects 0.000 title claims description 52
- 102000003706 Complement factor D Human genes 0.000 title claims description 46
- 108090000059 Complement factor D Proteins 0.000 title claims description 46
- 238000003556 assay Methods 0.000 claims description 63
- 230000000694 effects Effects 0.000 claims description 40
- 230000000295 complement effect Effects 0.000 claims description 37
- 206010018910 Haemolysis Diseases 0.000 claims description 36
- 230000008588 hemolysis Effects 0.000 claims description 36
- 108091034117 Oligonucleotide Proteins 0.000 claims description 31
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 31
- 239000003112 inhibitor Substances 0.000 claims description 29
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 28
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 20
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 20
- 230000001419 dependent effect Effects 0.000 claims description 18
- 108090000371 Esterases Proteins 0.000 claims description 16
- 150000003384 small molecules Chemical class 0.000 claims description 16
- 108091008102 DNA aptamers Proteins 0.000 claims description 15
- 108091008103 RNA aptamers Proteins 0.000 claims description 8
- SUGXUUGGLDCZKB-UHFFFAOYSA-N 3,4-dichloroisocoumarin Chemical group C1=CC=C2C(Cl)=C(Cl)OC(=O)C2=C1 SUGXUUGGLDCZKB-UHFFFAOYSA-N 0.000 claims description 6
- 238000009739 binding Methods 0.000 description 92
- 230000027455 binding Effects 0.000 description 90
- 239000000203 mixture Substances 0.000 description 90
- 238000000034 method Methods 0.000 description 70
- 206010064930 age-related macular degeneration Diseases 0.000 description 57
- 108090000056 Complement factor B Proteins 0.000 description 52
- 102000003712 Complement factor B Human genes 0.000 description 52
- 208000002780 macular degeneration Diseases 0.000 description 52
- 108090000623 proteins and genes Proteins 0.000 description 51
- 239000011324 bead Substances 0.000 description 49
- 102000004169 proteins and genes Human genes 0.000 description 49
- 229920001223 polyethylene glycol Polymers 0.000 description 48
- 210000004027 cell Anatomy 0.000 description 46
- 235000018102 proteins Nutrition 0.000 description 46
- 239000000872 buffer Substances 0.000 description 45
- 238000011282 treatment Methods 0.000 description 45
- 230000024203 complement activation Effects 0.000 description 42
- 208000022873 Ocular disease Diseases 0.000 description 41
- 239000002202 Polyethylene glycol Substances 0.000 description 38
- 230000006870 function Effects 0.000 description 35
- 208000027073 Stargardt disease Diseases 0.000 description 33
- 239000008194 pharmaceutical composition Substances 0.000 description 32
- 108020004414 DNA Proteins 0.000 description 31
- 108091008105 X-aptamers Proteins 0.000 description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 27
- 239000000758 substrate Substances 0.000 description 27
- 102100022133 Complement C3 Human genes 0.000 description 25
- 201000010099 disease Diseases 0.000 description 25
- 150000007523 nucleic acids Chemical class 0.000 description 25
- 125000003729 nucleotide group Chemical group 0.000 description 25
- 101000801643 Homo sapiens Retinal-specific phospholipid-transporting ATPase ABCA4 Proteins 0.000 description 24
- 239000002773 nucleotide Substances 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 23
- 102000039446 nucleic acids Human genes 0.000 description 23
- 108020004707 nucleic acids Proteins 0.000 description 23
- 102100033617 Retinal-specific phospholipid-transporting ATPase ABCA4 Human genes 0.000 description 22
- 238000012986 modification Methods 0.000 description 22
- 208000008069 Geographic Atrophy Diseases 0.000 description 21
- NCYCYZXNIZJOKI-OVSJKPMPSA-N Retinaldehyde Chemical compound O=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 21
- 230000005764 inhibitory process Effects 0.000 description 21
- 230000004048 modification Effects 0.000 description 21
- 210000002966 serum Anatomy 0.000 description 21
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 21
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 20
- 208000011325 dry age related macular degeneration Diseases 0.000 description 20
- 229920001427 mPEG Polymers 0.000 description 20
- 230000003321 amplification Effects 0.000 description 18
- 239000003153 chemical reaction reagent Substances 0.000 description 18
- 238000003199 nucleic acid amplification method Methods 0.000 description 18
- 229920000642 polymer Polymers 0.000 description 18
- 230000002401 inhibitory effect Effects 0.000 description 17
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 16
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 16
- 102000004196 processed proteins & peptides Human genes 0.000 description 16
- 230000002441 reversible effect Effects 0.000 description 16
- 239000003814 drug Substances 0.000 description 15
- 230000002207 retinal effect Effects 0.000 description 15
- 102000053602 DNA Human genes 0.000 description 14
- 238000010494 dissociation reaction Methods 0.000 description 14
- 230000005593 dissociations Effects 0.000 description 14
- 238000009472 formulation Methods 0.000 description 14
- 230000037361 pathway Effects 0.000 description 14
- 235000020945 retinal Nutrition 0.000 description 14
- 239000011604 retinal Substances 0.000 description 14
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 13
- 210000003743 erythrocyte Anatomy 0.000 description 13
- 230000035772 mutation Effects 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 13
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 13
- 230000008685 targeting Effects 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 12
- 229940088598 enzyme Drugs 0.000 description 12
- 230000000670 limiting effect Effects 0.000 description 12
- -1 pyrimidine nucleotide triphosphate analogs Chemical class 0.000 description 12
- 201000004569 Blindness Diseases 0.000 description 11
- 108010053085 Complement Factor H Proteins 0.000 description 11
- 102000016550 Complement Factor H Human genes 0.000 description 11
- 230000004913 activation Effects 0.000 description 11
- 238000003776 cleavage reaction Methods 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 238000002560 therapeutic procedure Methods 0.000 description 11
- 230000004393 visual impairment Effects 0.000 description 11
- BOMUADPKDXMXIH-UHFFFAOYSA-M 1,3-bis(1-methylquinolin-1-ium-6-yl)urea;methyl sulfate Chemical compound COS([O-])(=O)=O.COS([O-])(=O)=O.C[N+]1=CC=CC2=CC(NC(=O)NC=3C=C4C=CC=[N+](C4=CC=3)C)=CC=C21 BOMUADPKDXMXIH-UHFFFAOYSA-M 0.000 description 10
- 230000003247 decreasing effect Effects 0.000 description 10
- 229920001184 polypeptide Polymers 0.000 description 10
- 230000007017 scission Effects 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- 102000016574 Complement C3-C5 Convertases Human genes 0.000 description 9
- 108010067641 Complement C3-C5 Convertases Proteins 0.000 description 9
- 230000030833 cell death Effects 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 238000010828 elution Methods 0.000 description 9
- 238000000684 flow cytometry Methods 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 238000011534 incubation Methods 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 230000004304 visual acuity Effects 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 201000007737 Retinal degeneration Diseases 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 229960002319 barbital Drugs 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 238000012163 sequencing technique Methods 0.000 description 8
- FIWAQJRIROPAEC-IBGZPJMESA-N thiobenzyl benzyloxycarbonyl-L-lysinate Chemical compound N([C@@H](CCCCN)C(=O)SCC=1C=CC=CC=1)C(=O)OCC1=CC=CC=C1 FIWAQJRIROPAEC-IBGZPJMESA-N 0.000 description 8
- 108091081406 G-quadruplex Proteins 0.000 description 7
- 108020004682 Single-Stranded DNA Proteins 0.000 description 7
- 238000009825 accumulation Methods 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 230000009089 cytolysis Effects 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 108010010803 Gelatin Proteins 0.000 description 6
- 206010029113 Neovascularisation Diseases 0.000 description 6
- 230000003281 allosteric effect Effects 0.000 description 6
- 230000004154 complement system Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000008273 gelatin Substances 0.000 description 6
- 229920000159 gelatin Polymers 0.000 description 6
- 235000019322 gelatine Nutrition 0.000 description 6
- 235000011852 gelatine desserts Nutrition 0.000 description 6
- 230000001771 impaired effect Effects 0.000 description 6
- 210000001525 retina Anatomy 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 5
- 206010003694 Atrophy Diseases 0.000 description 5
- 102100032053 Elongation of very long chain fatty acids protein 4 Human genes 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 206010025421 Macule Diseases 0.000 description 5
- 208000035719 Maculopathy Diseases 0.000 description 5
- 150000001412 amines Chemical group 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 230000037444 atrophy Effects 0.000 description 5
- 230000004438 eyesight Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 239000003607 modifier Substances 0.000 description 5
- 210000000608 photoreceptor cell Anatomy 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 102220044643 rs587781450 Human genes 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- 101150039555 ABCA4 gene Proteins 0.000 description 4
- 108090000317 Chymotrypsin Proteins 0.000 description 4
- 208000010412 Glaucoma Diseases 0.000 description 4
- 101000737554 Homo sapiens Complement factor D Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 101710137500 T7 RNA polymerase Proteins 0.000 description 4
- 206010046851 Uveitis Diseases 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 229960002376 chymotrypsin Drugs 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 208000030533 eye disease Diseases 0.000 description 4
- 210000000744 eyelid Anatomy 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- 102000045507 human CFD Human genes 0.000 description 4
- 108091005601 modified peptides Proteins 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000000750 progressive effect Effects 0.000 description 4
- 230000006337 proteolytic cleavage Effects 0.000 description 4
- 230000004243 retinal function Effects 0.000 description 4
- 239000000790 retinal pigment Substances 0.000 description 4
- 238000000638 solvent extraction Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 238000007910 systemic administration Methods 0.000 description 4
- 150000007970 thio esters Chemical class 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 241000282693 Cercopithecidae Species 0.000 description 3
- 206010008786 Choroidal haemorrhage Diseases 0.000 description 3
- 208000002691 Choroiditis Diseases 0.000 description 3
- 102000000989 Complement System Proteins Human genes 0.000 description 3
- 108010069112 Complement System Proteins Proteins 0.000 description 3
- 230000006820 DNA synthesis Effects 0.000 description 3
- 206010061818 Disease progression Diseases 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 101000921354 Homo sapiens Elongation of very long chain fatty acids protein 4 Proteins 0.000 description 3
- 101000670189 Homo sapiens Ribulose-phosphate 3-epimerase Proteins 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 208000001344 Macular Edema Diseases 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- 240000008881 Oenanthe javanica Species 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 241001662443 Phemeranthus parviflorus Species 0.000 description 3
- 206010034960 Photophobia Diseases 0.000 description 3
- 208000003971 Posterior uveitis Diseases 0.000 description 3
- 206010038910 Retinitis Diseases 0.000 description 3
- 102000012479 Serine Proteases Human genes 0.000 description 3
- 108010022999 Serine Proteases Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000004350 Strabismus Diseases 0.000 description 3
- 206010047571 Visual impairment Diseases 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 108091036078 conserved sequence Proteins 0.000 description 3
- 230000004300 dark adaptation Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000006866 deterioration Effects 0.000 description 3
- 230000005750 disease progression Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 208000013469 light sensitivity Diseases 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 238000002887 multiple sequence alignment Methods 0.000 description 3
- 108091008104 nucleic acid aptamers Proteins 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 108091008695 photoreceptors Proteins 0.000 description 3
- 230000004962 physiological condition Effects 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 230000009290 primary effect Effects 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 150000003230 pyrimidines Chemical group 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- 208000029257 vision disease Diseases 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 102100022002 CD59 glycoprotein Human genes 0.000 description 2
- 208000002177 Cataract Diseases 0.000 description 2
- 208000033825 Chorioretinal atrophy Diseases 0.000 description 2
- 208000033810 Choroidal dystrophy Diseases 0.000 description 2
- 208000008515 Choroidal sclerosis Diseases 0.000 description 2
- 208000006992 Color Vision Defects Diseases 0.000 description 2
- 108090000044 Complement Factor I Proteins 0.000 description 2
- 102100035431 Complement factor I Human genes 0.000 description 2
- 206010010741 Conjunctivitis Diseases 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 description 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 2
- 206010013774 Dry eye Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108050007805 Elongation of very long chain fatty acids protein 4 Proteins 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 description 2
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 description 2
- 101000687592 Homo sapiens Retinol dehydrogenase 8 Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical group C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 206010061217 Infestation Diseases 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 206010025415 Macular oedema Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108010008148 Member 4 Subfamily A ATP Binding Cassette Transporter Proteins 0.000 description 2
- 102100039373 Membrane cofactor protein Human genes 0.000 description 2
- SOWBFZRMHSNYGE-UHFFFAOYSA-N Monoamide-Oxalic acid Natural products NC(=O)C(O)=O SOWBFZRMHSNYGE-UHFFFAOYSA-N 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 208000004788 Pars Planitis Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical group OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 101710188053 Protein D Proteins 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- 101710132893 Resolvase Proteins 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 102100028001 Retinaldehyde-binding protein 1 Human genes 0.000 description 2
- 101710101931 Retinaldehyde-binding protein 1 Proteins 0.000 description 2
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 2
- 102100024844 Retinol dehydrogenase 8 Human genes 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 206010039705 Scleritis Diseases 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- 208000025749 Vogt-Koyanagi-Harada disease Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 208000002205 allergic conjunctivitis Diseases 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 230000002391 anti-complement effect Effects 0.000 description 2
- 108010008730 anticomplement Proteins 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 210000000270 basal cell Anatomy 0.000 description 2
- 238000010256 biochemical assay Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 150000003857 carboxamides Chemical class 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 201000004709 chorioretinitis Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 201000007254 color blindness Diseases 0.000 description 2
- 230000004456 color vision Effects 0.000 description 2
- 230000001010 compromised effect Effects 0.000 description 2
- 201000007717 corneal ulcer Diseases 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000000779 depleting effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 238000007824 enzymatic assay Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 229960004198 guanidine Drugs 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 201000004614 iritis Diseases 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 206010023332 keratitis Diseases 0.000 description 2
- 150000002605 large molecules Chemical class 0.000 description 2
- 238000002898 library design Methods 0.000 description 2
- 150000002634 lipophilic molecules Chemical class 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 201000010230 macular retinal edema Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000007481 next generation sequencing Methods 0.000 description 2
- 230000004297 night vision Effects 0.000 description 2
- OKXGHXHZNCJMSV-UHFFFAOYSA-N nitro phenyl carbonate Chemical compound [O-][N+](=O)OC(=O)OC1=CC=CC=C1 OKXGHXHZNCJMSV-UHFFFAOYSA-N 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 206010030875 ophthalmoplegia Diseases 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 230000006320 pegylation Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical group [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 150000008300 phosphoramidites Chemical class 0.000 description 2
- 210000001127 pigmented epithelial cell Anatomy 0.000 description 2
- 229920000765 poly(2-oxazolines) Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 150000003212 purines Chemical group 0.000 description 2
- 239000002719 pyrimidine nucleotide Substances 0.000 description 2
- 238000004153 renaturation Methods 0.000 description 2
- 230000004283 retinal dysfunction Effects 0.000 description 2
- 230000004286 retinal pathology Effects 0.000 description 2
- 230000004268 retinal thickening Effects 0.000 description 2
- 201000007714 retinoschisis Diseases 0.000 description 2
- 238000013515 script Methods 0.000 description 2
- 208000027653 severe early-childhood-onset retinal dystrophy Diseases 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DTLVBHCSSNJCMJ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-[2-[2-[2-[2-[5-(2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl)pentanoylamino]ethoxy]ethoxy]ethoxy]ethoxy]propanoate Chemical compound S1CC2NC(=O)NC2C1CCCCC(=O)NCCOCCOCCOCCOCCC(=O)ON1C(=O)CCC1=O DTLVBHCSSNJCMJ-UHFFFAOYSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
- ZNQTYZYWDJGIBU-WBHUJUFNSA-N 1-[(2R,4S,5R)-2-[(3,4-dimethoxyphenyl)methyl]-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound COC=1C=C(C[C@@]2(C[C@H](O)[C@@H](CO)O2)N2C(=O)NC(=O)C=C2)C=CC=1OC ZNQTYZYWDJGIBU-WBHUJUFNSA-N 0.000 description 1
- JCMYQWLHARJCQS-JJRVBVJISA-N 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)-2-[(3-methoxyphenyl)methyl]oxolan-2-yl]pyrimidine-2,4-dione Chemical compound COC=1C=C(C[C@@]2(C[C@H](O)[C@@H](CO)O2)N2C(=O)NC(=O)C=C2)C=CC=1 JCMYQWLHARJCQS-JJRVBVJISA-N 0.000 description 1
- UOFROFMTGPJRJV-JJRVBVJISA-N 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)-2-[(4-methoxyphenyl)methyl]oxolan-2-yl]pyrimidine-2,4-dione Chemical compound COC1=CC=C(C[C@@]2(C[C@H](O)[C@@H](CO)O2)N2C(=O)NC(=O)C=C2)C=C1 UOFROFMTGPJRJV-JJRVBVJISA-N 0.000 description 1
- ZDGFRNRUIFMVLK-HBNTYKKESA-N 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-N-(2-methylpropyl)-2,4-dioxopyrimidine-5-carboxamide Chemical compound C(C(C)C)NC(=O)C=1C(NC(N([C@H]2C[C@H](O)[C@@H](CO)O2)C=1)=O)=O ZDGFRNRUIFMVLK-HBNTYKKESA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- MXHRCPNRJAMMIM-SHYZEUOFSA-N 2'-deoxyuridine Chemical group C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-SHYZEUOFSA-N 0.000 description 1
- BGCYSPBEPMOQII-UHFFFAOYSA-N 2,2,2-trifluoro-n-(6-hydroxyhexyl)acetamide Chemical compound OCCCCCCNC(=O)C(F)(F)F BGCYSPBEPMOQII-UHFFFAOYSA-N 0.000 description 1
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- RGNOTKMIMZMNRX-XVFCMESISA-N 2-amino-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-4-one Chemical compound NC1=NC(=O)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 RGNOTKMIMZMNRX-XVFCMESISA-N 0.000 description 1
- FINYOTLDIHYWPR-UHFFFAOYSA-N 2-cyanoethoxy-n,n-di(propan-2-yl)phosphonamidous acid Chemical compound CC(C)N(C(C)C)P(O)OCCC#N FINYOTLDIHYWPR-UHFFFAOYSA-N 0.000 description 1
- WKRRTOVSHXBUQD-IPMKNSEASA-N 4-(2,2-dimethylpropanoyl)-N-[3-[1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-2,4-dioxopyrimidin-5-yl]prop-2-enyl]benzamide Chemical compound C(C(C)(C)C)(=O)C1=CC=C(C(=O)NCC=CC=2C(NC(N([C@H]3C[C@H](O)[C@@H](CO)O3)C=2)=O)=O)C=C1 WKRRTOVSHXBUQD-IPMKNSEASA-N 0.000 description 1
- ZLOIGESWDJYCTF-UHFFFAOYSA-N 4-Thiouridine Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=S)C=C1 ZLOIGESWDJYCTF-UHFFFAOYSA-N 0.000 description 1
- ZLOIGESWDJYCTF-XVFCMESISA-N 4-thiouridine Chemical class O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=S)C=C1 ZLOIGESWDJYCTF-XVFCMESISA-N 0.000 description 1
- WAMWATABORFTJY-IVZWLZJFSA-N 5-(3-aminoprop-1-enyl)-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C=CCN)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 WAMWATABORFTJY-IVZWLZJFSA-N 0.000 description 1
- LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical class BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 1
- KSNXJLQDQOIRIP-UHFFFAOYSA-N 5-iodouracil Chemical class IC1=CNC(=O)NC1=O KSNXJLQDQOIRIP-UHFFFAOYSA-N 0.000 description 1
- WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 description 1
- 208000028048 Accommodation disease Diseases 0.000 description 1
- 201000009487 Amblyopia Diseases 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 208000005598 Angioid Streaks Diseases 0.000 description 1
- 102100034608 Angiopoietin-2 Human genes 0.000 description 1
- 201000002862 Angle-Closure Glaucoma Diseases 0.000 description 1
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 1
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 1
- 201000007978 Argyll Robertson pupil Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 208000020941 Benign concentric annular macular dystrophy Diseases 0.000 description 1
- 241000157302 Bison bison athabascae Species 0.000 description 1
- 206010005152 Blepharochalasis Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000016615 Central areolar choroidal dystrophy Diseases 0.000 description 1
- 208000003569 Central serous chorioretinopathy Diseases 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 201000005072 Chorioretinal scar Diseases 0.000 description 1
- 208000033379 Chorioretinopathy Diseases 0.000 description 1
- 208000024304 Choroidal Effusions Diseases 0.000 description 1
- 206010008783 Choroidal detachment Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 208000021089 Coats disease Diseases 0.000 description 1
- 201000003101 Coloboma Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108090000955 Complement C2 Proteins 0.000 description 1
- 102000004381 Complement C2 Human genes 0.000 description 1
- 108010028780 Complement C3 Proteins 0.000 description 1
- 108010034753 Complement Membrane Attack Complex Proteins 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 206010010984 Corneal abrasion Diseases 0.000 description 1
- 208000028006 Corneal injury Diseases 0.000 description 1
- 206010055665 Corneal neovascularisation Diseases 0.000 description 1
- MIKUYHXYGGJMLM-UUOKFMHZSA-N Crotonoside Chemical compound C1=NC2=C(N)NC(=O)N=C2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O MIKUYHXYGGJMLM-UUOKFMHZSA-N 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- 206010058202 Cystoid macular oedema Diseases 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 206010011841 Dacryoadenitis acquired Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 235000017274 Diospyros sandwicensis Nutrition 0.000 description 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 241000909851 Epiphora Species 0.000 description 1
- 208000001351 Epiretinal Membrane Diseases 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241001331845 Equus asinus x caballus Species 0.000 description 1
- 208000001692 Esotropia Diseases 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 201000005538 Exotropia Diseases 0.000 description 1
- 206010015901 Exudative retinopathy Diseases 0.000 description 1
- 208000020564 Eye injury Diseases 0.000 description 1
- 206010015995 Eyelid ptosis Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000014260 Fungal keratitis Diseases 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 208000036893 GUCY2D-related dominant retinopathy Diseases 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 206010018258 Giant papillary conjunctivitis Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 208000007698 Gyrate Atrophy Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 description 1
- 206010019864 Hereditary choroidal dystrophy Diseases 0.000 description 1
- 206010019899 Hereditary retinal dystrophy Diseases 0.000 description 1
- 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 description 1
- 206010020675 Hypermetropia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 206010062353 Keratitis fungal Diseases 0.000 description 1
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 description 1
- 201000002287 Keratoconus Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 201000003533 Leber congenital amaurosis Diseases 0.000 description 1
- 201000000639 Leber hereditary optic neuropathy Diseases 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 208000031471 Macular fibrosis Diseases 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100368144 Mus musculus Synb gene Proteins 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000001140 Night Blindness Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 230000004989 O-glycosylation Effects 0.000 description 1
- QUPYHFBXMYBAQB-DKVWWOGESA-N O1C(CCC1)C[C@]1(C[C@H](O)[C@@H](CO)O1)N1C(=O)NC(=O)C=C1 Chemical compound O1C(CCC1)C[C@]1(C[C@H](O)[C@@H](CO)O1)N1C(=O)NC(=O)C=C1 QUPYHFBXMYBAQB-DKVWWOGESA-N 0.000 description 1
- 206010030043 Ocular hypertension Diseases 0.000 description 1
- 208000021957 Ocular injury Diseases 0.000 description 1
- 241000243985 Onchocerca volvulus Species 0.000 description 1
- 206010030348 Open-Angle Glaucoma Diseases 0.000 description 1
- 208000009702 Optic Disk Drusen Diseases 0.000 description 1
- 208000036584 Optic disc drusen Diseases 0.000 description 1
- 206010061323 Optic neuropathy Diseases 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- 108010088535 Pep-1 peptide Proteins 0.000 description 1
- 206010034944 Photokeratitis Diseases 0.000 description 1
- 241000288935 Platyrrhini Species 0.000 description 1
- 229920000037 Polyproline Polymers 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 1
- 108010005642 Properdin Proteins 0.000 description 1
- 102100038567 Properdin Human genes 0.000 description 1
- 101710149951 Protein Tat Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 241000283011 Rangifer Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000037111 Retinal Hemorrhage Diseases 0.000 description 1
- 208000007135 Retinal Neovascularization Diseases 0.000 description 1
- 201000007527 Retinal artery occlusion Diseases 0.000 description 1
- 208000032436 Retinal depigmentation Diseases 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010038926 Retinopathy hypertensive Diseases 0.000 description 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 1
- 206010038934 Retinopathy proliferative Diseases 0.000 description 1
- 206010038935 Retinopathy sickle cell Diseases 0.000 description 1
- 208000032458 Retinopathy solar Diseases 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 241000593989 Scardinius erythrophthalmus Species 0.000 description 1
- 206010039729 Scotoma Diseases 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 208000036038 Subretinal fibrosis Diseases 0.000 description 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
- 101710192266 Tegument protein VP22 Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000031789 Thygeson superficial punctate keratitis Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- 208000001445 Uveomeningoencephalitic Syndrome Diseases 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 206010054880 Vascular insufficiency Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 208000034699 Vitreous floaters Diseases 0.000 description 1
- 208000034705 Vogt-Koyanagi-Harada syndrome Diseases 0.000 description 1
- 241000282485 Vulpes vulpes Species 0.000 description 1
- 206010048211 Xanthelasma Diseases 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 201000000761 achromatopsia Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000008303 aniridia Diseases 0.000 description 1
- 206010002537 anisometropia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000002137 anti-vascular effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical group OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 210000001775 bruch membrane Anatomy 0.000 description 1
- 108010040767 buforin I Proteins 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 208000003571 choroideremia Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 201000000159 corneal neovascularization Diseases 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 201000010206 cystoid macular edema Diseases 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 201000004400 dacryoadenitis Diseases 0.000 description 1
- 238000012350 deep sequencing Methods 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000011190 diabetic macular edema Diseases 0.000 description 1
- 150000001982 diacylglycerols Chemical class 0.000 description 1
- 150000001985 dialkylglycerols Chemical class 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 201000005412 disseminated chorioretinitis Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical group C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 201000003079 ectropion Diseases 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 206010014801 endophthalmitis Diseases 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 208000001936 exophthalmos Diseases 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 201000001258 focal chorioretinitis Diseases 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 201000006318 hyperopia Diseases 0.000 description 1
- 230000004305 hyperopia Effects 0.000 description 1
- 201000001948 hypertensive retinopathy Diseases 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Chemical group CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Chemical group C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000017532 inherited retinal dystrophy Diseases 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 208000016747 lacrimal apparatus disease Diseases 0.000 description 1
- 206010023683 lagophthalmos Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000011268 leukocyte chemotaxis Effects 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229940076783 lucentis Drugs 0.000 description 1
- 229940092110 macugen Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 230000004379 myopia Effects 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- VBRYAGCUEXFMKM-BFHYXJOUSA-N n-benzyl-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-2,4-dioxopyrimidine-5-carboxamide Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(=O)NCC=2C=CC=CC=2)=C1 VBRYAGCUEXFMKM-BFHYXJOUSA-N 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 201000003142 neovascular glaucoma Diseases 0.000 description 1
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 230000005257 nucleotidylation Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 201000005111 ocular hyperemia Diseases 0.000 description 1
- 208000003177 ocular onchocerciasis Diseases 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 208000020911 optic nerve disease Diseases 0.000 description 1
- 238000012014 optical coherence tomography Methods 0.000 description 1
- 208000014380 ornithine aminotransferase deficiency Diseases 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 230000026792 palmitoylation Effects 0.000 description 1
- 201000007407 panuveitis Diseases 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- MCYTYTUNNNZWOK-LCLOTLQISA-N penetratin Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 MCYTYTUNNNZWOK-LCLOTLQISA-N 0.000 description 1
- 108010043655 penetratin Proteins 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 201000003841 peripheral retinal degeneration Diseases 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 108010026466 polyproline Proteins 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000013823 prenylation Effects 0.000 description 1
- 201000010041 presbyopia Diseases 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 201000004616 primary angle-closure glaucoma Diseases 0.000 description 1
- 201000006366 primary open angle glaucoma Diseases 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000006785 proliferative vitreoretinopathy Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 201000003004 ptosis Diseases 0.000 description 1
- 239000002213 purine nucleotide Substances 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 208000032253 retinal ischemia Diseases 0.000 description 1
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 1
- 208000004644 retinal vein occlusion Diseases 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 238000012772 sequence design Methods 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 201000000824 solar retinopathy Diseases 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 108010066762 sweet arrow peptide Proteins 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 150000003573 thiols Chemical group 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 208000018657 thygeson superficial punctate keratopathy Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- PBKWZFANFUTEPS-CWUSWOHSSA-N transportan Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(N)=O)[C@@H](C)CC)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CC=C(O)C=C1 PBKWZFANFUTEPS-CWUSWOHSSA-N 0.000 description 1
- 108010062760 transportan Proteins 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229940117013 triethanolamine oleate Drugs 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229940056345 tums Drugs 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 208000023577 vascular insufficiency disease Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 108010047303 von Willebrand Factor Proteins 0.000 description 1
- 102100036537 von Willebrand factor Human genes 0.000 description 1
- 229960001134 von willebrand factor Drugs 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 208000005494 xerophthalmia Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662281092P | 2016-01-20 | 2016-01-20 | |
| US201662297095P | 2016-02-18 | 2016-02-18 | |
| PCT/US2017/014458 WO2017127761A1 (en) | 2016-01-20 | 2017-01-20 | Compositions and methods for inhibiting factor d |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| GB201718801D0 GB201718801D0 (en) | 2017-12-27 |
| GB2553252A GB2553252A (en) | 2018-02-28 |
| GB2553252A8 GB2553252A8 (en) | 2018-03-14 |
| GB2553252B true GB2553252B (en) | 2019-07-31 |
Family
ID=59362699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB1718801.2A Active GB2553252B (en) | 2016-01-20 | 2017-01-20 | Aptamers that block the catalytic cleft of complement Factor D |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US10174325B2 (enExample) |
| EP (1) | EP3405577B8 (enExample) |
| JP (3) | JP2019506159A (enExample) |
| CN (1) | CN108934169A (enExample) |
| AU (3) | AU2017210042B2 (enExample) |
| CA (1) | CA3011819A1 (enExample) |
| GB (1) | GB2553252B (enExample) |
| WO (1) | WO2017127761A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3110419A4 (en) | 2014-02-25 | 2017-07-26 | Achillion Pharmaceuticals, Inc. | Alkyne compounds for treatment of complement mediated disorders |
| WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
| WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
| WO2017035409A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
| AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| EP3405577B8 (en) | 2016-01-20 | 2023-02-15 | 396419 B.C. Ltd. | Compositions and methods for inhibiting factor d |
| WO2018136827A1 (en) | 2017-01-20 | 2018-07-26 | Vitrisa Therapeutics, Inc. | Stem-loop compositions and methods for inhibiting factor d |
| WO2018136831A1 (en) * | 2017-01-20 | 2018-07-26 | Vitrisa Therapeutics, Inc. | Pseudoknot compositions and methods for inhibiting factor d |
| CA3053818A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders |
| WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
| WO2019022986A1 (en) * | 2017-07-24 | 2019-01-31 | Vitrisa Therapeutics, Inc. | NUCLEIC ACID COMPOSITIONS AND METHODS OF INHIBITING D-FACTOR |
| WO2019028284A1 (en) | 2017-08-02 | 2019-02-07 | Achillion Pharmaceuticals, Inc. | THERAPEUTIC REGIMES FOR THE TREATMENT OF NOCTURNAL PAROXYSTIC HEMOGLOBINURIA |
| WO2019210194A1 (en) * | 2018-04-26 | 2019-10-31 | Vitrisa Therapeutics, Inc. | Pegylated compositions for ocular use, and methods thereof |
| JP7443375B2 (ja) | 2018-09-06 | 2024-03-05 | アキリオン ファーマシューティカルズ， インコーポレーテッド | 医学的障害の治療のための大環状化合物 |
| WO2020051538A1 (en) | 2018-09-06 | 2020-03-12 | Achillion Pharmaceuticals, Inc. | Morphic forms of complement factor d inhibitors |
| WO2020069024A1 (en) | 2018-09-25 | 2020-04-02 | Achillion Pharmaceuticals, Inc. | Morphic forms of complement factor d inhibitors |
| CN113195472A (zh) | 2018-12-17 | 2021-07-30 | 艾其林医药公司 | 用于治疗补体介导的病症的靶向给药 |
| WO2020146731A1 (en) * | 2019-01-11 | 2020-07-16 | Drive Therapeutics Llc | Compositions and methods for inhibiting vascular endothelial growth factor |
| MX2021011507A (es) | 2019-03-22 | 2021-12-15 | Achillion Pharmaceuticals Inc | Compuestos farmaceuticos para el tratamiento de trastornos mediados por complemento. |
| MX2022004939A (es) * | 2019-10-23 | 2022-08-10 | Gemini Therapeutics Sub Inc | Metodos para tratar pacientes que tienen mutaciones de cfh con proteinas de cfh recombinantes. |
| CN114686481B (zh) * | 2020-12-31 | 2023-08-15 | 北京键凯科技股份有限公司 | 一种抑制cfd表达的干扰rna及其制备方法和应用 |
| JP7829595B2 (ja) * | 2021-04-09 | 2026-03-13 | 武田薬品工業株式会社 | 補体因子ｄを標的とする抗体及びその使用 |
| CN121969751A (zh) * | 2023-10-11 | 2026-05-01 | 瑞泽恩制药公司 | 使用补体因子d (cfd)抑制剂治疗黄斑变性 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015168468A1 (en) * | 2014-05-01 | 2015-11-05 | Genentech, Inc. | Anti-factor d antibody variants and uses thereof |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| ATE318832T1 (de) | 1990-06-11 | 2006-03-15 | Gilead Sciences Inc | Verfahren zur vervendung von nukleinsäureliganden |
| US6140490A (en) | 1996-02-01 | 2000-10-31 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands of complement system proteins |
| WO1998055471A1 (en) | 1997-06-03 | 1998-12-10 | Biocryst Pharmaceuticals, Inc. | Novel compounds useful in the complement, coagulat and kallikrein pathways and method for their preparation |
| AU756490B2 (en) | 1997-08-26 | 2003-01-16 | Abgenix, Inc. | A process for inhibiting complement activation via the alternative pathway |
| WO1999027133A1 (en) | 1997-11-26 | 1999-06-03 | Medical Research Council | Improved selex procedure and an anti-cd4 aptamer |
| US6956107B2 (en) | 1998-02-20 | 2005-10-18 | Tanox, Inc. | Inhibitors of complement activation |
| US7112327B2 (en) | 1998-02-20 | 2006-09-26 | Tanox, Inc. | Inhibition of complement activation |
| GB9930659D0 (en) | 1999-12-24 | 2000-02-16 | Bio Discovery Ltd | Inhibitors of complement activation |
| US6998468B2 (en) | 2000-03-23 | 2006-02-14 | Tanox, Inc. | Anti-C2/C2a inhibitors of complement activation |
| EP1594541A4 (en) | 2003-02-21 | 2007-03-28 | Rikshospitalet Radiumhospitale | METHOD AND COMPOSITIONS FOR TREATING MECONIUM ASPIRATION SYNDROME |
| BRPI0506629A (pt) | 2004-02-10 | 2007-05-02 | Univ Colorado | inibição do fator b, a via alternativa do sistema complemento e métodos relacionados |
| US7803931B2 (en) | 2004-02-12 | 2010-09-28 | Archemix Corp. | Aptamer therapeutics useful in the treatment of complement-related disorders |
| EP1861114B1 (en) | 2005-03-11 | 2011-02-02 | Potentia Pharmaceuticals, Inc. | Compositions comprising modulators of g-protein-coupled receptor for treatment of macular degeneration |
| CN103505728A (zh) | 2005-05-26 | 2014-01-15 | 科罗拉多大学评议会法人机构 | 用于治疗外伤性脑损伤、脊髓损伤及相关病症的补体旁路抑制 |
| US8168584B2 (en) * | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
| KR101126423B1 (ko) | 2005-10-21 | 2012-07-11 | 카탈리스트 바이오사이언시즈, 인코포레이티드 | 보체 활성화를 억제하는 변형된 프로테아제 |
| DK2500030T4 (en) | 2005-11-04 | 2018-10-29 | Genentech Inc | Use of complement pathway inhibitors for the treatment of eye diseases |
| AU2006337093B2 (en) | 2005-12-22 | 2013-03-14 | Opko Pharmaceuticals, Llc. | Compositions and methods for regulating complement system |
| JP2009521506A (ja) | 2005-12-22 | 2009-06-04 | アルコン リサーチ， リミテッド | 補体因子ｈの危険である改変体をもつ患者における年齢による斑状変性の予防および処置のためのｃ３コンバターゼインヒビター |
| US20070196367A1 (en) | 2006-02-22 | 2007-08-23 | Valentin Dinu | Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system |
| DK1991275T3 (en) | 2006-03-08 | 2014-12-08 | Archemix Llc | Complement aptamers AND ANTI-C5 AGENTS FOR USE IN THE TREATMENT OF EYE DISEASES |
| LT3028716T (lt) | 2006-10-10 | 2020-12-10 | Regenesance B.V. | Komplemento slopinimas nervų regeneracijos pagerinimui |
| US8790924B2 (en) | 2006-10-19 | 2014-07-29 | Duke University | Reversible platelet inhibition |
| CN106084055A (zh) | 2006-11-02 | 2016-11-09 | 健泰科生物技术公司 | 人源化的抗‑d因子抗体 |
| EP2148691B1 (en) | 2007-02-05 | 2015-05-20 | Apellis Pharmaceuticals, Inc. | Compstatin analogues for use in the treatment of inflammatory conditions of the respiratory system |
| RU2009144142A (ru) * | 2007-04-30 | 2011-06-10 | Алькон Рисерч, Лтд. (Us) | Лечение возрастной дегенерации желтого пятна с применением ингибиторов фактора d комплемента |
| AR066660A1 (es) * | 2007-05-23 | 2009-09-02 | Genentech Inc | Prevencion y tratamiento de condiciones del ojo asociadas con su complemento |
| US20090092980A1 (en) | 2007-07-20 | 2009-04-09 | Christoph Arenz | miRNA PROCESSING INHIBITOR EFFICACY ASSAYS AND SUBSTANCES |
| US8981060B2 (en) | 2007-08-27 | 2015-03-17 | Novelmed Therapuetics, Inc. | Method of inhibiting complement activation with factor Bb specific antibodies |
| GB0718737D0 (en) | 2007-09-25 | 2007-11-07 | Glaxo Group Ltd | Antibodies |
| CA2707859A1 (en) | 2007-12-11 | 2009-06-18 | Glaxo Group Limited | Antigen binding proteins specific against beta amyloid |
| CA2718588A1 (en) | 2008-02-19 | 2009-08-27 | The Trustees Of The University Of Pennsylvania | Complement inhibitors as therapeutic agents for treatment of cancer |
| US8940299B2 (en) | 2008-02-28 | 2015-01-27 | Case Western Reserve University | Method of treating cancer |
| DK2262831T3 (en) | 2008-03-03 | 2015-04-27 | Novelmed Therapeutics Inc | ANTI-Properdin ANTIBODIES |
| US8664362B2 (en) | 2008-03-03 | 2014-03-04 | NovelMed Therapeutics | Humanized and chimeric anti-properdin antibodies |
| WO2009121065A2 (en) | 2008-03-28 | 2009-10-01 | Apellis Ag | Modulation and repletion/enhancement of the complement system for treatment of trauma |
| CR20170001A (es) | 2008-04-28 | 2017-08-10 | Genentech Inc | Anticuerpos anti factor d humanizados |
| EP2159286A1 (en) | 2008-09-01 | 2010-03-03 | Consiglio Nazionale Delle Ricerche | Method for obtaining oligonucleotide aptamers and uses thereof |
| WO2010030789A1 (en) | 2008-09-10 | 2010-03-18 | Novelmed Therapeutics, Inc. | Device and method for inhibiting complement activation |
| GB0904427D0 (en) * | 2009-03-13 | 2009-04-29 | Lachmann Peter | Treatment of diseases related to hyperactivity of the complement system |
| US9382544B2 (en) | 2009-05-15 | 2016-07-05 | Nec Solution Innovators, Ltd. | Aptamer that recognizes peptide |
| JP5871798B2 (ja) | 2009-07-02 | 2016-03-01 | エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント | 肝再生を刺激する方法 |
| WO2011007876A1 (ja) | 2009-07-16 | 2011-01-20 | Ｎｅｃソフト株式会社 | Ｈｍｇｂ１結合核酸分子およびその用途 |
| US20120190578A1 (en) | 2009-08-06 | 2012-07-26 | Washington University | Plasma Complement Components as Expression Markers for Age-Related Macular Degeneration and Related Phenotypes |
| US20110165648A1 (en) | 2009-11-04 | 2011-07-07 | Menno Van Lookeren Campagne | Co-crystal structure of factor D and anti-factor D antibody |
| KR20130130732A (ko) | 2010-11-01 | 2013-12-02 | 제넨테크, 인크. | 다유전자 스코어를 이용한 진행성 노인성 황반 변성으로의 진행 예측 |
| CN103402996B (zh) | 2011-01-04 | 2015-02-11 | 诺瓦提斯公司 | 可用于治疗年龄相关性黄斑变性(amd)的吲哚化合物或其类似物 |
| CA2840270C (en) | 2011-06-22 | 2023-09-26 | Apellis Pharmaceuticals, Inc. | Methods of treating chronic disorders with complement inhibitors |
| US10966945B2 (en) | 2011-08-01 | 2021-04-06 | Aurin Biotech Inc. | Selective inhibition of the membrane attack complex of complement by low molecular weight components of the aurin tricarboxylic synthetic complex |
| EP2762569B1 (en) | 2011-09-28 | 2018-06-13 | RIBOMIC Inc. | Ngf aptamer and application thereof |
| MX355567B (es) | 2011-12-30 | 2018-04-23 | Quest Diagnostics Invest Inc | Aptameros y metodos de diagnostico para detectar el receptor de egf. |
| ES2749624T3 (es) | 2013-03-14 | 2020-03-23 | Caribou Biosciences Inc | Composiciones y métodos de ácidos nucleicos dirigidos a ácido nucleico |
| MX2016001854A (es) | 2013-08-12 | 2016-09-06 | Genentech Inc | Composiciones y metodo para tratar condiciones asociadas con el complemento. |
| US20150104445A1 (en) | 2013-10-10 | 2015-04-16 | Viropharma Holdings Limited | Methods of inhibiting the alternative pathway of complement immune system activation and compositions used therein |
| EP3110419A4 (en) | 2014-02-25 | 2017-07-26 | Achillion Pharmaceuticals, Inc. | Alkyne compounds for treatment of complement mediated disorders |
| TWI623617B (zh) | 2014-08-29 | 2018-05-11 | 國立清華大學 | 對卵巢癌具有專一性之適合體及其應用 |
| JP2018535679A (ja) | 2015-11-19 | 2018-12-06 | ベース ペア バイオテクノロジーズ，インク． | 標的分子の高感度検出のための方法及び材料 |
| WO2017127762A1 (en) | 2016-01-20 | 2017-07-27 | Vitrisa Therapeutics, Inc. | Methods for improved aptamer selection |
| EP3405577B8 (en) | 2016-01-20 | 2023-02-15 | 396419 B.C. Ltd. | Compositions and methods for inhibiting factor d |
| EP3414330A4 (en) | 2016-02-08 | 2019-07-03 | Vitrisa Therapeutics, Inc. | COMPOSITIONS WITH IMPROVED INTRAVITREAL HALF TIME AND USES THEREOF |
| WO2018136831A1 (en) | 2017-01-20 | 2018-07-26 | Vitrisa Therapeutics, Inc. | Pseudoknot compositions and methods for inhibiting factor d |
| WO2018136827A1 (en) | 2017-01-20 | 2018-07-26 | Vitrisa Therapeutics, Inc. | Stem-loop compositions and methods for inhibiting factor d |
| WO2019022986A1 (en) | 2017-07-24 | 2019-01-31 | Vitrisa Therapeutics, Inc. | NUCLEIC ACID COMPOSITIONS AND METHODS OF INHIBITING D-FACTOR |
-
2017
- 2017-01-20 EP EP17742071.8A patent/EP3405577B8/en active Active
- 2017-01-20 CA CA3011819A patent/CA3011819A1/en active Pending
- 2017-01-20 CN CN201780018764.5A patent/CN108934169A/zh active Pending
- 2017-01-20 JP JP2018538551A patent/JP2019506159A/ja active Pending
- 2017-01-20 WO PCT/US2017/014458 patent/WO2017127761A1/en not_active Ceased
- 2017-01-20 GB GB1718801.2A patent/GB2553252B/en active Active
- 2017-01-20 AU AU2017210042A patent/AU2017210042B2/en active Active
- 2017-08-31 US US15/693,361 patent/US10174325B2/en active Active
-
2018
- 2018-09-04 US US16/121,458 patent/US20190161755A1/en not_active Abandoned
-
2020
- 2020-01-14 US US16/742,741 patent/US11274307B2/en active Active
-
2021
- 2021-04-20 AU AU2021202392A patent/AU2021202392B2/en active Active
-
2022
- 2022-03-14 JP JP2022039070A patent/JP2022078283A/ja active Pending
-
2023
- 2023-04-27 AU AU2023202548A patent/AU2023202548A1/en not_active Abandoned
- 2023-12-27 JP JP2023220791A patent/JP2024029136A/ja active Pending
-
2024
- 2024-07-05 US US18/765,089 patent/US20250197868A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015168468A1 (en) * | 2014-05-01 | 2015-11-05 | Genentech, Inc. | Anti-factor d antibody variants and uses thereof |
Non-Patent Citations (2)
| Title |
|---|
| Biotechnology and Bioengineering, 2015, vol. 112, no. 8, , OUELLET, E. et al., "Hi-Fi SELEX: A High-Fidelity Digital-PCR Based Therapeutic Aptamer Discovery Platform", pages 1506 - 1522 * |
| Chemical Communications, 2014, vol. 50, no. 63, LAO, Y.H. et al., "Selection of Aptamers Targeting the Sialic Acid Receptor of Hemagglutinin by Epitope-Specific SELEX", pages 8719 - 8722, * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024029136A (ja) | 2024-03-05 |
| US11274307B2 (en) | 2022-03-15 |
| JP2019506159A (ja) | 2019-03-07 |
| WO2017127761A1 (en) | 2017-07-27 |
| US20250197868A1 (en) | 2025-06-19 |
| US20190161755A1 (en) | 2019-05-30 |
| US20180051287A1 (en) | 2018-02-22 |
| AU2017210042A1 (en) | 2018-07-26 |
| EP3405577B1 (en) | 2022-12-14 |
| CA3011819A1 (en) | 2017-07-27 |
| AU2017210042B2 (en) | 2021-01-21 |
| CN108934169A (zh) | 2018-12-04 |
| GB2553252A8 (en) | 2018-03-14 |
| US10174325B2 (en) | 2019-01-08 |
| GB2553252A (en) | 2018-02-28 |
| GB201718801D0 (en) | 2017-12-27 |
| AU2021202392B2 (en) | 2023-02-02 |
| AU2023202548A1 (en) | 2023-06-01 |
| JP2022078283A (ja) | 2022-05-24 |
| HK1251610A1 (zh) | 2019-02-01 |
| EP3405577A1 (en) | 2018-11-28 |
| AU2021202392A1 (en) | 2021-05-20 |
| US20200392502A1 (en) | 2020-12-17 |
| EP3405577B8 (en) | 2023-02-15 |
| EP3405577A4 (en) | 2019-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250197868A1 (en) | Compositions and methods for inhibiting factor d | |
| RU2477137C2 (ru) | Связывающие комплемент аптамеры и средства против с5, пригодные для лечения глазных нарушений | |
| JP2012528597A (ja) | 血小板グリコプロテインｖｉの核酸調節因子 | |
| US11466276B2 (en) | Stem-loop compositions and methods for inhibiting factor D | |
| WO2018136831A1 (en) | Pseudoknot compositions and methods for inhibiting factor d | |
| US12534734B2 (en) | Stem-loop compositions and methods for inhibiting interleukin-8 | |
| WO2019022986A1 (en) | NUCLEIC ACID COMPOSITIONS AND METHODS OF INHIBITING D-FACTOR | |
| WO2020247850A1 (en) | Compositions and methods for inhibiting angiopoietin-2 | |
| US12540330B2 (en) | Stem-loop compositions and methods for inhibiting vascular endothelial growth factor | |
| AU2022202115A1 (en) | Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders | |
| JP2021507253A (ja) | Ｈｔｒａ１ ｒｎａアンタゴニストについてのコンパニオン診断 | |
| WO2026104891A2 (en) | Multi-valent anti-c5 molecules | |
| WO2020146731A1 (en) | Compositions and methods for inhibiting vascular endothelial growth factor | |
| AU2020201145A1 (en) | Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1251610 Country of ref document: HK |
|
| 732E | Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977) |
Free format text: REGISTERED BETWEEN 20201112 AND 20201118 |